Literature DB >> 19374704

Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives.

Jacqueline A Guidry1, James N George, Sara K Vesely, Shelia M Kennison, Deirdra R Terrell.   

Abstract

OBJECTIVES: The purpose of this study was to examine hematologist and patient perspectives about the side-effects of the corticosteroid treatment of immune thrombocytopenic purpura (ITP) and their perspectives about the patient's risk for bleeding. The specific aim was to compare patient and hematologist perspectives and, if a difference was documented, the implications of that difference. We hypothesized that patients with ITP may have more concern about corticosteroid side-effects and less concern about serious bleeding than hematologists.
METHODS: We surveyed 80 patients in the Oklahoma ITP Registry and all 83 hematologists in Oklahoma about the occurrence and severity of 18 corticosteroid side-effects and risks for serious bleeding.
RESULTS: Response rates were 80% (patients) and 71% (hematologists). Responses of patients and hematologists were significantly different from each other regarding both the frequency of severe corticosteroid side-effects and the risk of serious bleeding. For 13 of the 18 corticosteroid side-effects, patients reported more frequent occurrence of severe symptoms than hematologists (P < 0.05); physicians reported more frequent occurrence for one side-effect (P < 0.05). Conversely, 69% and 93% of hematologists reported being very worried about serious bleeding when responding to two case scenarios describing patients with platelet counts of 10 000/microL and 5000/microL (P < 0.05), compared with only 16 (31%) of 51 patients whose lowest platelet count had been <10 000/microL.
CONCLUSION: Awareness of the different opinions about corticosteroid side-effects and risk for bleeding between ITP patients and hematologists may improve management decisions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374704     DOI: 10.1111/j.1600-0609.2009.01265.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.

Authors:  Zhenyu Li; Weiwei Mou; Guang Lu; Jiang Cao; Xupeng He; Xiuying Pan; Kailin Xu
Journal:  Int J Hematol       Date:  2010-12-29       Impact factor: 2.490

2.  Definition, diagnosis and treatment of immune thrombocytopenic purpura.

Authors:  James N George
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

4.  Clinical Practice Updates in the Management Of Immune Thrombocytopenia.

Authors:  Ayesha M Khan; Halina Mydra; Ana Nevarez
Journal:  P T       Date:  2017-12

5.  Prevalence of primary immune thrombocytopenia in Oklahoma.

Authors:  Deirdra R Terrell; Laura A Beebe; Barbara R Neas; Sara K Vesely; Jodi B Segal; James N George
Journal:  Am J Hematol       Date:  2012-06-05       Impact factor: 10.047

Review 6.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

7.  Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists.

Authors:  Allyson M Pishko; Mudi Misgav; Adam Cuker; Douglas B Cines; James N George; Sara K Vesely; Deirdra R Terrell
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

8.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

Authors:  Philip Yi Choi; Eileen Merriman; Ashwini Bennett; Anoop K Enjeti; Chee Wee Tan; Isaac Goncalves; Danny Hsu; Robert Bird
Journal:  Med J Aust       Date:  2021-10-10       Impact factor: 12.776

9.  Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.

Authors:  Peter Joseph Jongen; Ioanna Stavrakaki; Bernard Voet; Erwin Hoogervorst; Erik van Munster; Wim H Linssen; Ludovicus G Sinnige; Wim I Verhagen; Leo H Visser; Ruud van der Kruijk; Freek Verheul; Jan Boringa; Marco Heerings; Werner Gladdines; Fredrik Lönnqvist; Pieter Gaillard
Journal:  J Neurol       Date:  2016-06-07       Impact factor: 4.849

10.  Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia.

Authors:  Zongtang Liu; Meiying Wang; Shufen Zhou; Ji Ma; Yan Shi; Jun Peng; Ming Hou; Chengshan Guo
Journal:  J Transl Med       Date:  2016-10-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.